Article: Early Stage Improvement
Source: CapsugelĀ® | Lonza Pharma & Biotech
Jan Vertommen at Capsugel looks at enhancing the bioavailability of compounds for early stage clinical trials
Improving the bioavailability of orally administered waterinsoluble compounds is allowing pharma and biotech companies to generate more representative pharmacokinetic and safety data from their first-in-human trials. Improving the quality of data at this early stage could contribute to the success of the FDA’s Critical Path Initiative’s strategy of ‘failing faster’, helping to ensure that the safest and most effective drugs secure the resources required to reach the marketplace more quickly.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
This website uses cookies to ensure you get the best experience on our website. Learn more